(-0.20%) 5 136.50 points
(-0.14%) 38 505 points
(-0.17%) 17 873 points
(0.38%) $82.94
(2.32%) $2.08
(-1.47%) $2 323.10
(-2.96%) $26.84
(-1.32%) $948.80
(0.01%) $0.932
(0.31%) $11.02
(0.09%) $0.797
(0.07%) $93.37
@ $0.562
Išleistas: 12 vas. 2024 @ 18:22
Grąža: -22.95%
Ankstesnis signalas: vas. 7 - 18:41
Ankstesnis signalas:
Grąža: 4.13 %
Live Chart Being Loaded With Signals
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults...
Stats | |
---|---|
Šios dienos apimtis | 380 888 |
Vidutinė apimtis | 603 533 |
Rinkos kapitalizacija | 12.86M |
EPS | $-22.40 ( 2024-03-10 ) |
Kita pelno data | ( $0 ) 2024-06-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0.110 |
ATR14 | $0.00200 (0.46%) |
Tūris Koreliacija
Redhill Biopharma Ltd Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
TTCF | 0.968 |
LNSR | 0.963 |
VIRX | 0.961 |
WISA | 0.959 |
IMRX | 0.957 |
NOTV | 0.956 |
IMCC | 0.955 |
SRZN | 0.955 |
SNCE | 0.954 |
FATE | 0.95 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
MGI | -0.956 |
CCRC | -0.944 |
PWOD | -0.942 |
STIM | -0.937 |
NWFL | -0.935 |
IMMR | -0.933 |
ROST | -0.93 |
HZNP | -0.929 |
ACAHU | -0.924 |
EWEB | -0.924 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Redhill Biopharma Ltd Koreliacija - Valiuta/Žaliavos
Redhill Biopharma Ltd Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $6.51M |
Bruto pelnas: | $3.06M (47.03 %) |
EPS: | $3.68 |
FY | 2023 |
Pajamos: | $6.51M |
Bruto pelnas: | $3.06M (47.03 %) |
EPS: | $3.68 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
Pajamos: | $61.80M |
Bruto pelnas: | $28.46M (46.06 %) |
EPS: | $-38.27 |
Financial Reports:
No articles found.
Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.